1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with ergoline in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (29.63) | 18.7374 |
| 1990's | 16 (59.26) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bédard, PJ; Boucher, R; Gomez-Mancilla, B | 1 |
| Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF | 1 |
| Close, SP; Elliott, PJ; Walsh, DM | 1 |
| Bruno, JP; Hadjiconstantinou, M; Weihmuller, FB | 1 |
| Brown, A; Dali, H; Neumeyer, JL; Pihan, G; Szabo, S | 1 |
| Bédard, PJ; Boucher, R | 1 |
| Schneider, JS | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Jenner, P; Marsden, CD; Nomoto, M | 2 |
| Jenner, P; Marsden, CD | 1 |
| Bankiewicz, K; Brücke, T; Harvey-White, J; Kopin, I | 1 |
| Johnson, BJ; Peacock, V; Schneider, JS | 1 |
| Erol, DD; Gnanalingham, KK; Hunter, AJ; Jenner, P; Marsden, CD; Smith, LA | 1 |
| Gnanalingham, KK; Hunter, AJ; Jenner, P; Marsden, CD | 1 |
| Drukarch, B; Goosen, C; Sahadat, MC; Stoof, JC; Vermeulen, RJ; Wolters, EC | 1 |
| Roeltgen, DP; Schneider, JS; Sun, ZQ | 1 |
| Drukarch, B; Goosen, C; Sahadat, MC; Stoof, JC; van Royen, EA; Verhoeff, NP; Vermeulen, RJ; Wolters, EC | 1 |
| Kuno, S; Mizuta, E; Sasa, M; Yoshida, O; Yoshimura, N | 1 |
| Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E | 1 |
| Arai, N; Isaji, M; Kojima, M; Kuno, S; Mizuta, E | 1 |
| Fukuda, T; Iwata, SI; Kaseda, S; Kita, S; Nomoto, M | 1 |
| Bédard, PJ; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M | 2 |
| Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A | 1 |
| Di Paolo, T; Morissette, M; Parent, M; Riahi, G | 1 |
1 review(s) available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and ergoline
| Article | Year |
|---|---|
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
26 other study(ies) available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and ergoline
| Article | Year |
|---|---|
Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electromyography; Ergolines; Female; Indoles; Injections, Subcutaneous; Macaca fascicularis; Parkinson Disease, Secondary; Phenanthridines; Quinpirole; Tremor | 1992 |
Effect of ethosuximide on rest tremor in the MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diltiazem; Dopamine Agents; Dose-Response Relationship, Drug; Electromyography; Ergolines; Ethosuximide; Female; Macaca fascicularis; Neurologic Examination; Parkinson Disease, Secondary; Quinpirole; Tremor; Verapamil | 1992 |
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Dopamine Agents; Ergolines; Female; Levodopa; Male; Movement; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1992 |
Dopamine receptors and sensorimotor behavior in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Arousal; Benzazepines; Discrimination Learning; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Haloperidol; Male; Mice; Mice, Inbred Strains; Motor Activity; Orientation; Quinpirole; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride | 1990 |
Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amylases; Animals; Bicarbonates; Bromocriptine; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenum; Ergolines; Female; Gastric Acid; Gastric Emptying; Gastrointestinal Motility; Monoamine Oxidase Inhibitors; Pancreas; Pyridines; Rats; Rats, Inbred Strains; Trypsin | 1985 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Ergolines; Female; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine; Receptors, Dopamine D1; Sulpiride | 1989 |
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Quinpirole | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug; Ergolines; Injections, Intravenous; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Quinpirole; Stereotyped Behavior | 1989 |
The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Dopamine Agents; Ergolines; Female; Male; Motor Activity; Pyridines; Quinpirole | 1988 |
The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzazepines; Callitrichinae; Ergolines; Female; Male; Parkinson Disease, Secondary; Pyridines; Quinpirole; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1985 |
The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ergolines; Female; Lisuride; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine | 1988 |
Dihydrexidine, a full D1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Ergolines; Functional Laterality; Macaca mulatta; Male; Parkinson Disease, Secondary; Phenanthridines; Quinpirole; Raclopride; Receptors, Dopamine D1; Rotation; Salicylamides | 1995 |
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Binding, Competitive; Callithrix; Dopamine Agonists; Ergolines; In Vitro Techniques; Male; Parkinson Disease, Secondary; Quinpirole; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Spiperone | 1995 |
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylyl Cyclases; Animals; Behavior, Animal; Callithrix; Dopamine Agonists; Ergolines; Female; In Vitro Techniques; Male; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D1; Species Specificity | 1995 |
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Macaca mulatta; Male; Motor Activity; Motor Skills; Parkinson Disease, Secondary; Psychomotor Performance; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra | 1994 |
Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Conditioning, Operant; Dopamine Agents; Ergolines; Female; Macaca; Male; Methylphenidate; Psychomotor Performance; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1994 |
No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Animals; Behavior, Animal; Benzamides; Binding, Competitive; Dopamine Agents; Dopamine D2 Receptor Antagonists; Ergolines; Functional Laterality; Macaca mulatta; Male; Neostriatum; Pyrrolidines; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2; Rotation; Stereotyped Behavior; Tomography, Emission-Computed, Single-Photon | 1994 |
The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dopamine Agents; Ergolines; Macaca fascicularis; Male; Parkinson Disease, Secondary; Quinpirole; Reflex; Urinary Bladder; Urination | 1993 |
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide | 1995 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary | 1996 |
Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cabergoline; Callithrix; Dopamine Agents; Dopamine Agonists; Ergolines; Female; Male; Motor Activity; Parkinson Disease, Secondary | 1998 |
Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Brain Chemistry; Cabergoline; Corpus Striatum; Denervation; Dopamine Agents; Dopamine Agonists; Enkephalins; Ergolines; Female; Gene Expression; Macaca fascicularis; Movement Disorders; Protein Precursors; Pulsatile Flow; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Tachykinins | 1999 |
Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Benzazepines; Cabergoline; Denervation; Dopamine Agonists; Ergolines; Female; Flunitrazepam; gamma-Aminobutyric Acid; Macaca fascicularis; Ovariectomy; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA-A; Tritium | 1999 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Benzazepines; Benzoates; Binding Sites; Brain; Cabergoline; Corpus Striatum; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Ergolines; Female; GABA Antagonists; GABA-B Receptor Antagonists; Injections, Subcutaneous; Iodine Radioisotopes; Macaca fascicularis; Organophosphorus Compounds; Parkinson Disease, Secondary; Receptors, GABA-B; Substantia Nigra; Thalamus | 2000 |
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Ergolines; Female; Locomotion; Macaca fascicularis; Parkinson Disease; Posture | 2003 |
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A | 2011 |